This brief will present a snapshot of hepatitis B and C testing in the European Union/European Economic Area (EU/EEA), discussing progress made towards the European action plan 2020 testing target, focussing on key populations and settings for testing, barriers to testing, and testing policies.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
Smallpox was once a common, deadly disease, that killed a third of those who contracted it. 200 years ago, it was discovered that vaccination could prevent smallpox. Learn more about the fight against smallpox in our videos
Smallpox was once a common, deadly disease, that killed a third of those who contracted it. 200 years ago, it was discovered that vaccination could prevent smallpox. Learn more about the fight against smallpox in our video (turn on subtitles in your language)!